Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082105 | 0.89 | CRHR1 (0.46) | CRHR1S1PR4 | |
| SCHEMBL6081726 | 0.84 | S1PR4 (0.39) | CRHR1S1PR4KDM4EMAPTMAPK1 | |
| SCHEMBL6082084 | 0.83 | CRHR1 (0.38) | CRHR1S1PR4KDM4EMAPTMAPK1 | |
| SCHEMBL6083042 | 0.82 | CRHR1 (0.45) | CRHR1CYP2D6DRD1HTR2AADORA1 | |
| SCHEMBL6817723 | 0.82 | CRHR1 (0.38) | CRHR1S1PR4KDM4EMAPTMAPK1 | |
| SCHEMBL6082472 | 0.81 | CRHR1 (0.36) | CRHR1S1PR4KDM4EMAPTMAPK1 | |
| SCHEMBL6818369 | 0.80 | S1PR4 (0.37) | CRHR1S1PR4KDM4EMAPTMAPK1 | |
| SCHEMBL6082998 | 0.80 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL6082337 | 0.79 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL6082375 | 0.78 | CRHR1 (0.44) | CRHR1KDM4EMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067658-B2 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-29 | — | — | US | disclosed |
| WO-2004031189-A1 | PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082784-A1 | Pyridino and pyrimidino pyrazinones | CRHR1, CRHR2, CRH | CRHR1 1/4885CYP2D6 1128/4885DRD1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.